Novo Nordisk A/S
Stocks making the biggest moves midday: UnitedHealth, Alibaba, Hims & Hers Health, Celsius and more
Check out the companies making headlines in midday trading: Novo Nordisk — Shares rose 4.9% after the Food and Drug Administration said Friday that the U.S. shortage of Novo Nordisk’s weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years. Hims & Hers Health — The telehealth stock, which offers compounded Wegovy and […]
Read More
Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters The long-running U.S. shortage of Novo Nordisk‘s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said on Friday. The FDA’s decision will threaten the […]
Read More
Shortage of Novo’s Wegovy and Ozempic is resolved, FDA website shows
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A shortage of Danish drugmaker Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration’s website showed on […]
Read More
Healthy Returns: Ozempic helps curb alcohol use in new study — and doctors are concerned about telehealth GLP-1s
Steve Christo | Corbis News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk‘s blockbuster diabetes drug Ozempic may also help people drink less alcohol. That’s according to new government-funded research […]
Read More
Trump’s reciprocal tariffs would hit these European Union products that Americans buy the hardest
Workers walk past manufacturing equipment at Eli Lilly & Co. manufacturing plant in Kinsale, Ireland, on Sept. 12, 2024. Lilly has been bulking up its production capacity since 2020, investing more than $17 billion into developing new plants and expanding existing facilities for the weight-loss and diabetes drugs that are expected to become some of […]
Read More
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading’ patients
Hims & Hers is facing scrutiny from lawmakers over an advertisement for its weight loss offerings that’s slated to run during the Super Bowl on Sunday. Sens. Dick Durbin, D-Ill., and Roger Marshall, R-Kan., wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an “upcoming advertisement” that “risks misleading […]
Read More
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a […]
Read More
Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs
It’s been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo’s obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo’s stock has fallen more than 20% over the last year, […]
Read More
Stocks making the biggest moves midday: Alphabet, Apple, Uber, Nvidia and more
Check out the companies making headlines in midday trading. Alphabet — Shares sank nearly 8% after the Google parent reported fourth-quarter revenue of $96.47 billion, short of the $96.56 billion expected from analysts polled by LSEG. Alphabet also said it will invest $75 billion in 2025 as it expands its artificial-intelligence strategy, versus the $58.84 […]
Read More